{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:05:26Z","timestamp":1784167526738,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biosci"],"DOI":"10.1007\/s12038-026-00607-w","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:44:39Z","timestamp":1784166279000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergistic effects of sorafenib and cilostazol in HepG2 cells"],"prefix":"10.1007","volume":"51","author":[{"given":"Heba","family":"Effat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omnia A","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Sharaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Heikal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrouk","family":"Elshahawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2970-3397","authenticated-orcid":false,"given":"Eman G","family":"Ayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"607_CR1","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.31557\/APJCP.2021.22.9.2951","volume":"22","author":"AHA Abdel Wahab","year":"2021","unstructured":"Abdel Wahab AHA, Ayad EG, Abdulla MS, et al. 2021 Induction of anti-proliferative and apoptotic effects of sorafenib using miR-27a inhibitor in hepatocellular carcinoma cell lines. Asian Pac. J. Cancer Prev. 22 2951\u20132958","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"607_CR2","first-page":"1695","volume":"42","author":"AA Bahman","year":"2018","unstructured":"Bahman AA, Abaza MSI, Khoushiash SI, et al. 2018 Sequence-dependent effect of sorafenib in combination with natural phenolic compounds on hepatic cancer cells and the possible mechanism of action. Int. J. Mol. Med. 42 1695\u20131715","journal-title":"Int. J. Mol. Med."},{"key":"607_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/JHC.S61146","volume":"3","author":"J Balogh","year":"2016","unstructured":"Balogh J, Victor D III, Asham EH, et al. 2016 Hepatocellular carcinoma: a review. J. Hepatocell. Carcinoma 3 41\u201353","journal-title":"J. Hepatocell. Carcinoma"},{"key":"607_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1042\/CS20160438","volume":"131","author":"F Cauchy","year":"2017","unstructured":"Cauchy F, Mebarki M, Leporq B, et al. 2017 Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis. Clin. Sci. 131 27\u201336","journal-title":"Clin. Sci."},{"key":"607_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC 2006 Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58 621\u2013681","journal-title":"Pharmacol. Rev."},{"key":"607_CR31","doi-asserted-by":"crossref","unstructured":"Donne R and Lujambio A 2023 The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology 77 1773\u20131796","DOI":"10.1002\/hep.32740"},{"key":"607_CR6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1586\/egh.10.58","volume":"4","author":"A Duffy","year":"2010","unstructured":"Duffy A and Greten TF 2010 Advances in hepatocellular carcinoma treatment. Expert Rev. Gastroenterol. Hepatol. 4 551\u2013560","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"607_CR7","first-page":"5193","volume":"11","author":"AR El-Zayadi","year":"2005","unstructured":"El-Zayadi AR, Badran HM, Barakat EM, et al. 2005 Hepatocellular carcinoma in Egypt: a single center study over a decade. World J. Gastroenterol. 11 5193","journal-title":"World J. Gastroenterol."},{"key":"607_CR9","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.3390\/cancers13133248","volume":"13","author":"E Gonzalez-Sanchez","year":"2021","unstructured":"Gonzalez-Sanchez E, Vaquero J, F\u00e9rnandez-Barrena MG, et al. 2021 The TGF-\u03b2 pathway: a pharmacological target in hepatocellular carcinoma? Cancers 13 3248","journal-title":"Cancers"},{"key":"607_CR10","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1016\/j.bbrc.2018.08.098","volume":"503","author":"C He","year":"2018","unstructured":"He C, Wu T and Hao Y 2018 Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway. Biochem. Biophys. Res. Commun. 503 3093\u20133099","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"607_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jjcc.2015.05.003","volume":"67","author":"H Ishii","year":"2016","unstructured":"Ishii H, Aoyama T, Takahashi H, et al. 2016 Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease. J. Cardiol. 67 199\u2013204","journal-title":"J. Cardiol."},{"key":"607_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.fct.2016.12.018","volume":"100","author":"Y Kangawa","year":"2017","unstructured":"Kangawa Y, Yoshida T, Maruyama K, et al. 2017 Cilostazol and enzymatically modified isoquercitrin attenuate experimental colitis and colon cancer in mice by inhibiting cell proliferation and inflammation. Food Chem. Toxicol. 100 103\u2013114","journal-title":"Food Chem. Toxicol."},{"key":"607_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11523-017-0484-7","volume":"12","author":"GM Keating","year":"2017","unstructured":"Keating GM 2017 Sorafenib: a review in hepatocellular carcinoma. Target Oncol. 12 243\u2013253","journal-title":"Target Oncol."},{"key":"607_CR14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ and Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method. Methods 25 402\u2013408","journal-title":"Methods"},{"key":"607_CR15","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","volume":"2","author":"JM Llovet","year":"2016","unstructured":"Llovet JM, Zucman-Rossi J, Pikarsky E, et al. 2016 Hepatocellular carcinoma. Nat. Rev. Dis. Primers 2 16018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"607_CR8","doi-asserted-by":"crossref","unstructured":"MaruYama T, Chen W and Shibata H 2022 TGF-\u03b2 and cancer immunotherapy. Biol. Pharm. Bull. 45 155\u2013161","DOI":"10.1248\/bpb.b21-00966"},{"key":"607_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","volume":"134","author":"J Massagu\u00e9","year":"2008","unstructured":"Massagu\u00e9 J 2008 TGF\u03b2 in cancer. Cell 134 215\u2013230","journal-title":"Cell"},{"key":"607_CR17","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1073\/pnas.85.14.5126","volume":"85","author":"WE Russell","year":"1988","unstructured":"Russell WE, Coffey RJ, Ouellette AJ, et al. 1988 Transforming growth factor-beta and liver cancer. Proc. Natl. Acad. Sci. USA 85 5126\u20135130","journal-title":"Proc. Natl. Acad. Sci."},{"key":"607_CR18","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s00535-010-0270-0","volume":"45","author":"YC Shen","year":"2010","unstructured":"Shen YC, Hsu C and Cheng AL 2010 Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J. Gastroenterol. 45 794\u2013807","journal-title":"J. Gastroenterol."},{"key":"607_CR19","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s12257-021-0002-8","volume":"26","author":"KH Sim","year":"2021","unstructured":"Sim KH, Shu MS, Kim S, et al. 2021 Cilostazol induces apoptosis and inhibits proliferation of hepatocellular carcinoma cells by activating AMPK. Biotechnol. Bioprocess Eng. 26 776\u2013785","journal-title":"Biotechnol. Bioprocess Eng."},{"key":"607_CR20","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","volume":"82","author":"P Skehan","year":"1990","unstructured":"Skehan P, Storeng R, Scudiero D, et al. 1990 New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82 1107\u20131112","journal-title":"J. Natl. Cancer Inst."},{"key":"607_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.557","volume":"5","author":"R Sonntag","year":"2014","unstructured":"Sonntag R, Gassler N, Bangen JM, et al. 2014 Pro-apoptotic sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo. Cell Death Dis. 5 e1030","journal-title":"Cell Death Dis."},{"key":"607_CR22","doi-asserted-by":"publisher","first-page":"17889","DOI":"10.1038\/s41598-022-21582-w","volume":"12","author":"AM Taha","year":"2022","unstructured":"Taha AM, Aboulwafa MM, Zedan H, et al. 2022 Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells. Sci. Rep. 12 17889","journal-title":"Sci. Rep."},{"key":"607_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052852","volume":"8","author":"S Theodoropoulou","year":"2013","unstructured":"Theodoropoulou S, Brodowska K, Kayama M, et al. 2013 Aminoimidazole carboxamide ribonucleotide (AICAR) inhibits the growth of retinoblastoma in vivo by decreasing angiogenesis and inducing apoptosis. PLoS One 8 e52852","journal-title":"PLoS One"},{"key":"607_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/cam4.56","volume":"2","author":"K Uzawa","year":"2013","unstructured":"Uzawa K, Kasamatsu A, Baba T, et al. 2013 Targeting phosphodiesterase 3 B enhances cisplatin sensitivity in human cancer cells. Cancer Med. 2 40\u201349","journal-title":"Cancer Med."},{"key":"607_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2012.10.021","volume":"329","author":"H van Malenstein","year":"2013","unstructured":"van Malenstein H, Dekervel J, Verslype C, et al. 2013 Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett. 329 74\u201383","journal-title":"Cancer Lett."},{"key":"607_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10555-023-10084-4","volume":"42","author":"Y Wang","year":"2023","unstructured":"Wang Y and Deng B 2023 Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev. 42 629\u2013652","journal-title":"Cancer Metastasis Rev."},{"key":"607_CR27","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1111\/cas.13570","volume":"109","author":"JC Wang","year":"2018","unstructured":"Wang JC, Li XX, Sun X, et al. 2018 Activation of AMPK by simvastatin inhibited breast tumor angiogenesis via impeding HIF-1\u03b1-induced pro-angiogenic factor. Cancer Sci. 109 1627\u20131637","journal-title":"Cancer Sci."},{"key":"607_CR28","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, et al. 2004 BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64 7099\u20137109","journal-title":"Cancer Res."},{"key":"607_CR29","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.7150\/ijbs.89568","volume":"20","author":"X Xin","year":"2024","unstructured":"Xin X, Cheng X, Zeng F, et al. 2024 The role of TGF-\u03b2\/SMAD signaling in hepatocellular carcinoma: from mechanism to therapy and prognosis. Int. J. Biol. Sci. 20 1436\u20131451","journal-title":"Int. J. Biol. Sci."},{"key":"607_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.836333","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhang Y, Shi XJ, et al. 2022 Chenodeoxycholic acid enhances the effect of sorafenib in inhibiting HepG2 cell growth through EGFR\/Stat3 pathway. Front. Oncol. 12 836333","journal-title":"Front. Oncol."}],"container-title":["Journal of Biosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12038-026-00607-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12038-026-00607-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12038-026-00607-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:44:40Z","timestamp":1784166280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12038-026-00607-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["607"],"URL":"https:\/\/doi.org\/10.1007\/s12038-026-00607-w","relation":{},"ISSN":["0973-7138"],"issn-type":[{"value":"0973-7138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"25 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"35"}}